Effect of bepotastine besilate and levocetrizine in urticaria disease of ski
- Conditions
- Health Condition 1: L500- Allergic urticariaHealth Condition 2: null- diagnosis of CSU (EAACI), characterized by erythematous skin wheals accompanied by itching of unknown etiology will be recruited.
- Registration Number
- CTRI/2017/10/010232
- Lead Sponsor
- Dr E Gayathri
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 100
Male and female patients, aged 18-70 years old, with a diagnosis of CSU (EAACI), characterized by erythematous skin wheals accompanied by itching of unknown etiology will be recruited.
Eligible patients should demonstrate Symptom score of >=2 (i.e. moderate to severe intensity UAS7 scores) during the baseline visit.
Patients willing to give informed consent will be included.
Patients excluded from the study if they have any dermatological condition that could interfere with the efficacy evaluation (including eczema, contact dermatitis, atopic dermatitis, nummular eczema, autosensitization dermatitis, asteatotic eczema, lichen simplex chronicus, angioedema, , urticaria with known causes, urticaria related to thyroid disorders, urticaria pigmentosa, psoriasis, or ichthyosis
o Known hypersensitivity to antihistamine,
oKnown autoimmune disorders, Hodgkins disease
oAny clinically significant condition (cardiovascular, neurological, hepatic, renal, or malignant diseases),
oReceived ultraviolet light therapy before entry.
oSimilarly, patients who had received antihistamines (including H2 receptor antagonists) within 3 days, nonsteroidal anti-inflammatory drugs within 3 days, topical or systemic steroids within 4 weeks, astemizole within 6 weeks, ketotifen within 2 weeks, anti-Leukotrienes within 3 days.
oPregnant and lactating women.
oSubject who is currently enrolled in another investigational drug study
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method